Sidley advised Jiangsu Hengrui Medicine Co., Ltd., a leading biopharmaceutical company in China, in entering into a license agreement with CrystalGenomics, Inc., a South Korea-based biopharmaceutical company. Under the agreement, Hengrui grants an exclusive license to CrystalGenomics for the development, regulatory approval and commercialization of Camrelizumab, a PD-1 monoclonal antibody, in South Korea. Hengrui will be entitled to receive a total of up to US$87.75 million in upfront and milestone payments as well as royalties based on the net sales of the licensed product by CrystalGenomics. The Sidley team was led by Technology and IP Transactions partner Thomas Duley (San Francisco) and M&A/Private Equity partner Ruchun Ji (Shanghai and Palo Alto).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
